

## Regimen list

| Regimen                                                                                                | Status   |
|--------------------------------------------------------------------------------------------------------|----------|
| - Hypersensitivity - As Required Medications - Version 3                                               | Active   |
| 5-Fluorouracil (4 day) and mitoMYcin Chemoradiation - Version 4                                        | Active   |
| 5-Fluorouracil (5 day) and mitoMYcin Chemoradiation - Version 2                                        | Inactive |
| 5-fluorouracil 225mg/m <sup>2</sup> /day and Radiotherapy (RT)-Continuous infusion (7 day) - Version 6 | Active   |
| 5-Fluorouracil and Folinic Acid Therapy-14 day Adj - Version 3                                         | Active   |
| 5-Fluorouracil and Folinic Acid Therapy-14 day- Met - Version 2                                        | Active   |
| 5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) - Version 1                              | Inactive |
| 5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC 50) Therapy - Version 2                        | Inactive |
| Abiraterone 1000mg and Prednisolone 5mg - Version 2                                                    | Active   |
| Abiraterone and Prednisolone - Version 4                                                               | Active   |
| ABVD - Version 4                                                                                       | Active   |
| Afatinib Monotherapy - Version 2                                                                       | Active   |
| Aflibercept and FOLFIRI -14 day - Version 1                                                            | Inactive |
| Alectinib Monotherapy - Version 1                                                                      | Active   |
| Anastrozole Monotherapy Adj - Version 4                                                                | Active   |
| Anastrozole Monotherapy LA/M - Version 3                                                               | Active   |
| Apalutamide - Version 1                                                                                | Active   |
| Atezolizumab 1200mg Monotherapy - Version 1                                                            | Active   |
| Atezolizumab and nab-PACLitaxel - Version 2                                                            | Inactive |
| Avelumab Monotherapy - Version 2                                                                       | Inactive |
| Axitinib Monotherapy - Version 2                                                                       | Active   |
| azaCITIDine 100mg/m <sup>2</sup> 5-day - Version 5                                                     | Active   |
| azaCITIDine 75mg/m <sup>2</sup> 5-2-2 - Version 5                                                      | Active   |
| BEAM Autologous Transplant Conditioning Protocol - Version 1                                           | Inactive |
| Bendamustine Monotherapy - Version 1                                                                   | Inactive |
| Bevacizumab 10mg/kg - 14 days - Version 3                                                              | Active   |
| Bevacizumab 15mg/kg - 21 days - Version 4                                                              | Active   |
| Bevacizumab 5mg/kg -14 days - Version 2                                                                | Inactive |
| Bevacizumab 5mg/kg and FOLFIRI – 14 days - Version 3                                                   | Active   |
| Bevacizumab 5mg/kg and Modified FOLFOX- 6 – 14 days - Version 4                                        | Active   |
| Bevacizumab 7.5mg/kg – 21 days - Version 4                                                             | Active   |
| Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m <sup>2</sup> Therapy- 21 day - Version 1                | Active   |
| Bevacizumab 7.5mg/kg, CARBOplatin(AUC5) and PACLitaxel 175mg/m <sup>2</sup> - Version 2                | Active   |
| Bicalutamide - Version 2                                                                               | Active   |
| Bleomycin, Etoposide and CISplatin (BEP) - Version 2                                                   | Active   |
| Bortezomib and Dexamethasone - Version 4                                                               | Active   |
| Bortezomib Maintenance - 14 day - Version 3                                                            | Active   |
| Bortezomib, Lenalidomide and Dexamethasone (RVD) - 21 day - Version 3                                  | Inactive |
| Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day - Version 2                          | Active   |
| Bortezomib, Melphalan & Prednisolone - Version 2                                                       | Active   |
| Bortezomib, Thalidomide and Dexamethasone (VTD) Induction - Version 2                                  | Active   |
| Bosutinib Monotherapy - Version 1                                                                      | Inactive |
| Brentuximab vedotin and Bendamustine - Version 1                                                       | Active   |
| Brentuximab vedotin and ESHAP (BRESHAP) - Version 1                                                    | Active   |
| Brentuximab vedotin and ICE - Version 3                                                                | Active   |
| Brentuximab vedotin Monotherapy - Version 2                                                            | Active   |
| Brigatinib - Version 3                                                                                 | Active   |
| Busulfan,Cyclophosphamide – MAC – SIB - Version 2                                                      | Active   |
| Busulfan,Cyclophosphamide,ATG Grafalon® – MAC – Mismatched Sibling Donor - Version 2                   | Active   |
| Busulfan,Cyclophosphamide,ATG Grafalon® – MAC – Mismatched Unrelated Donor - Version 2                 | Active   |
| Busulfan,Cyclophosphamide–MAC–MUD - Version 2                                                          | Active   |
| Cabazitaxel and Prednisolone - Version 2                                                               | Active   |
| Cabozantinib - Version 3                                                                               | Active   |
| Capecitabine 825mg/m <sup>2</sup> and RT-7 day - Version 2                                             | Active   |
| Capecitabine and Oxaliplatin Therapy (XELOX) Adj - Version 3                                           | Active   |

## Regimen list

| Regimen                                                                                                                                                             | Status   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| Capecitabine and Oxaliplatin Therapy (XELOX) Met - Version 3                                                                                                        | Active   |
| Capecitabine and RT – 7 day - Version 4                                                                                                                             | Active   |
| Capecitabine and Temozolomide - Version 2                                                                                                                           | Active   |
| Capecitabine Monotherapy Adj - Version 4                                                                                                                            | Active   |
| Capecitabine Monotherapy LA/M - Version 4                                                                                                                           | Inactive |
| CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m <sup>2</sup> ) Weekly with Radiotherapy (RT) -5 weeks - Version 8                                                 | Active   |
| CARBOplatin (AUC 2) Weekly with Radiotherapy (RT) - Version 6                                                                                                       | Active   |
| CARBOplatin (AUC 3), Etoposide (50mg/m <sup>2</sup> ) and Thoracic Radiotherapy (TRT) -28 day - Version 2                                                           | Active   |
| CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m <sup>2</sup> /day – 28 day - Version 6                                                                              | Active   |
| CARBOplatin (AUC 6) and PACLitaxel 200mg/m <sup>2</sup> - Version 4                                                                                                 | Inactive |
| CARBOplatin (AUC1.5) Chemoradiation - 7 days - Version 4                                                                                                            | Active   |
| CARBOplatin (AUC5) and Etoposide 100mg/m <sup>2</sup> - 21 days - Version 8                                                                                         | Active   |
| CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m <sup>2</sup> 6 cycles - Version 1                                                                                   | Active   |
| CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m <sup>2</sup> Adj - Version 1                                                                                        | Active   |
| CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m <sup>2</sup> followed by Dose Dense DOXorubicin Cyclophosphamide Therapy- Triple Negative Breast Cancer - Version 4 | Active   |
| CARBOplatin 70mg/m <sup>2</sup> and 5-Fluorouracil 600mg/m <sup>2</sup> with Radiotherapy - Version 2                                                               | Active   |
| CARBOplatin and Oral Etoposide - 21days - Version 4                                                                                                                 | Active   |
| CARBOplatin and vinORElbine Therapy-21 Day - Version 1                                                                                                              | Inactive |
| CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m <sup>2</sup> with Radiotherapy - Version 3                                                                             | Active   |
| CARBOplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m <sup>2</sup> Therapy-28 day - Version 1                                                                | Inactive |
| CARBOplatin AUC4 Monotherapy-21 days - Version 4                                                                                                                    | Active   |
| CARBOplatin AUC4 Monotherapy-28 days - Version 4                                                                                                                    | Active   |
| CARBOplatin AUC5 and PACLitaxel 175mg/m <sup>2</sup> Adj - Version 5                                                                                                | Active   |
| CARBOplatin AUC5 and PACLitaxel 175mg/m <sup>2</sup> Met - Version 4                                                                                                | Active   |
| CARBOplatin AUC5 Monotherapy-21 days - Version 4                                                                                                                    | Active   |
| CARBOplatin AUC5 Monotherapy-28 days - Version 4                                                                                                                    | Active   |
| CARBOplatin AUC6 and PACLitaxel 175mg/m <sup>2</sup> Adj - Version 4                                                                                                | Active   |
| CARBOplatin AUC6 and PACLitaxel 175mg/m <sup>2</sup> Met - Version 5                                                                                                | Active   |
| CARBOplatin AUC6 Monotherapy-21 days - Version 6                                                                                                                    | Active   |
| CARBOplatin AUC6 Monotherapy-28 days - Version 6                                                                                                                    | Active   |
| CARBOplatin AUC7 and PACLitaxel 175mg/m <sup>2</sup> Adj - Version 4                                                                                                | Active   |
| CARBOplatin AUC7 and PACLitaxel 175mg/m <sup>2</sup> Met - Version 4                                                                                                | Active   |
| CARBOplatin AUC7.5 and PACLitaxel 175mg/m <sup>2</sup> Adj - Version 7                                                                                              | Active   |
| CARBOplatin AUC7.5 and PACLitaxel 175mg/m <sup>2</sup> Met - Version 7                                                                                              | Active   |
| Carfilzomib (20/70mg/m <sup>2</sup> Once weekly) Dexamethasone (Kd) therapy - 28 day - Version 1                                                                    | Inactive |
| Carfilzomib (27mg/m <sup>2</sup> twice weekly), Lenalidomide and Dexamethasone (KRd) - 28 day - Version 3                                                           | Inactive |
| Carfilzomib (56mg/m <sup>2</sup> once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day - Version 1                                                     | Active   |
| Carfilzomib and Dexamethasone (Kd) - 28 day - Version 4                                                                                                             | Active   |
| Carmustine,Etoposide,Cytarabine,Melphalan,Alemtuzumab RIC-SIB/MUD - Version 2                                                                                       | Active   |
| Ceritinib Monotherapy - Version 1                                                                                                                                   | Active   |
| Cetuximab - 7 day (12 weeks) - Version 4                                                                                                                            | Active   |
| Cetuximab - 7 day (8 weeks) - Version 4                                                                                                                             | Active   |
| Cetuximab (14 days) and FOLFIRI (14 days) - Version 2                                                                                                               | Active   |
| Cetuximab (14 days) and Irinotecan (14 days) - Version 2                                                                                                            | Active   |
| Cetuximab (7 days) and FOLFIRI (14 days) Therapy - Version 4                                                                                                        | Active   |
| Cetuximab (7 days) and Irinotecan (14 days) - Version 2                                                                                                             | Active   |
| Cetuximab (weekly), CARBOplatin AUC 5 and 5-Fluorouracil 1000mg/m <sup>2</sup> /day - 21 day cycle - Version 8                                                      | Active   |
| Cetuximab (weekly), CISplatin 100mg/m <sup>2</sup> and 5-Fluorouracil 1000mg/m <sup>2</sup> /day - 21 day cycle - Version 5                                         | Inactive |
| CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and ONE dose gemtuzumab ozogamicin (for patients ≥1 year and >10kg and BSA ≥ 0.5m <sup>2</sup> ) - Version 1   | Inactive |

## Regimen list

| Regimen                                                                                                                                                                                    | Status   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and THREE dose gemtuzumab ozogamicin (for patients $\geq 1$ year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$ ) - Version 1 | Inactive |
| CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and TWO dose Gemtuzumab Ozogamicin ( $<1$ year or $\leq 10\text{kg}$ or $\text{BSA} <0.5\text{m}^2$ ) - Version 1                     | Inactive |
| CHI AML MyeChild Course 2 - FLA IDA (for HR patients $<1$ year or $\leq 10\text{kg}$ or $\text{BSA} <0.5\text{m}^2$ ) - Version 1                                                          | Inactive |
| CHI AML MyeChild Course 2 – FLA IDA (for HR patients $\geq 1$ year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$ ) - Version 1                                                    | Inactive |
| CHI AML MyeChild Course 2 - mitoXANTRONE, Cytarabine (for non HR patients $<1$ year or $\leq 10\text{kg}$ or $\text{BSA} <0.5\text{m}^2$ ) - Version 1                                     | Inactive |
| CHI AML MyeChild Course 2 - mitoXANTRONE, Cytarabine (for non HR patients $\geq 1$ year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$ ) - Version 1                               | Inactive |
| CHI AML MyeChild Course 3 - FLA (for HR patients $\geq 1$ year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$ ) - Version 1                                                        | Inactive |
| CHI AML MyeChild Course 3 - FLA (for HR patients $<1$ year or $\leq 10\text{kg}$ or $\text{BSA} <0.5\text{m}^2$ ) - Version 1                                                              | Inactive |
| CHI AML MyeChild Course 3 - FLA IDA (for IR and HR patients $<1$ year or $\leq 10\text{kg}$ or $\text{BSA} <0.5\text{m}^2$ ) - Version 1                                                   | Inactive |
| CHI AML MyeChild Course 3 - FLA IDA (for IR and HR patients $\geq 1$ year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$ ) - Version 1                                             | Inactive |
| CHI AML MyeChild Course 3 and 4 - FLA (for SR patient $\geq 1$ year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$ ) - Version 1                                                   | Inactive |
| CHI AML MyeChild Course 3 and 4 - FLA (for SR patients $<1$ year or $\leq 10\text{kg}$ or $\text{BSA} <0.5\text{m}^2$ ) - Version 1                                                        | Inactive |
| CHI AML MyeChild Course 3 and 4 - HD Cytarabine (for SR patients $<1$ year or $\leq 10\text{kg}$ or $\text{BSA} <0.5\text{m}^2$ ) - Version 1                                              | Inactive |
| CHI AML MyeChild Course 3 and 4 - HD Cytarabine (for SR patients $\geq 1$ year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$ ) - Version 1                                        | Inactive |
| CHI AML MyeChild Course 4 - High Dose Cytarabine (for IR patients $<1$ year or $\leq 10\text{kg}$ or $\text{BSA} <0.5\text{m}^2$ ) - Version 1                                             | Inactive |
| CHI AML MyeChild Course 4 - High Dose Cytarabine (for IR patients $\geq 1$ year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$ ) - Version 1                                       | Inactive |
| CHI ES VDC/IE Induction Euro Ewing 2012 - Version 2                                                                                                                                        | Inactive |
| Chlorambucil $10\text{mg}/\text{m}^2$ - Version 2                                                                                                                                          | Active   |
| CHOEP – 21 days - Version 2                                                                                                                                                                | Active   |
| CISplatin ( $100\text{mg}/\text{m}^2$ ) with Radiotherapy (RT) - 21 day - Version 7                                                                                                        | Active   |
| CISplatin ( $40\text{mg}/\text{m}^2$ ) Weekly with Radiotherapy (RT) (5 cycles) - Version 8                                                                                                | Active   |
| CISplatin ( $40\text{mg}/\text{m}^2$ ) Weekly with Radiotherapy (RT) (6 cycles) - Version 7                                                                                                | Active   |
| CISplatin ( $50\text{mg}/\text{m}^2$ ) and Etoposide ( $50\text{mg}/\text{m}^2$ ) and Thoracic Radiotherapy (TRT) -28 day - Version 4                                                      | Active   |
| CISplatin ( $50\text{mg}/\text{m}^2$ ) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel ( $175\text{mg}/\text{m}^2$ ) – Endometrial Cancer - Version 2                        | Active   |
| CISplatin ( $75\text{mg}/\text{m}^2$ ) + Etoposide - 21 day - Version 6                                                                                                                    | Active   |
| CISplatin ( $75\text{mg}/\text{m}^2$ ) + Etoposide ( $100\text{mg}/\text{m}^2$ ) +Thoracic Radiotherapy (TRT) -21 day - Version 6                                                          | Active   |
| CISplatin $75\text{mg}/\text{m}^2$ and 5-Fluorouracil Chemoradiation - Herskovic Regimen - Version 5                                                                                       | Active   |
| CISplatin and 5-Fluorouracil- 28 day cycle - Version 1                                                                                                                                     | Inactive |
| CISplatin and Capecitabine Adjuvant Chemoradiation - Version 1                                                                                                                             | Inactive |
| CISplatin, 5-Fluorouracil and Radiation Therapy - Version 2                                                                                                                                | Active   |
| CISplatin, Methotrexate and vinBLASTine (CMV) - Version 1                                                                                                                                  | Inactive |
| Cladribine $0.14\text{mg}/\text{kg}$ Day 1 to 5 Therapy - Version 2                                                                                                                        | Active   |
| Cladribine $0.14\text{mg}/\text{kg}$ Weekly - Version 3                                                                                                                                    | Active   |
| Cladribine 5 day and ritUXimab - Version 2                                                                                                                                                 | Active   |
| Cladribine Weekly and ritUXimab - Version 1                                                                                                                                                | Inactive |
| Crizotinib Monotherapy - Version 4                                                                                                                                                         | Active   |
| Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Adj - Version 4                                                                                                         | Active   |
| Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Met - Version 3                                                                                                         | Active   |
| Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 day Adj - Version 1                                                                                                         | Inactive |
| Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Met - Version 1                                                                                                         | Inactive |
| Cyclophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Met - Version 2                                                                                                              | Active   |

## Regimen list

| Regimen                                                                                                                                        | Status   |
|------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| Cyclophosphamide(Oral) Methotrexate and 5-Fluorouracil (CMF) Adj - Version 2                                                                   | Active   |
| Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day - Version 3                                                                     | Active   |
| Cyclophosphamide, DOXOrubicin, vinCRISTine and prednisoLONE (CHOP) Therapy– 21 days - Version 2                                                | Active   |
| Cyclophosphamide,Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor - Version 2                                                         | Active   |
| Cyclophosphamide,Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor - Version 1                                                       | Active   |
| Cyclophosphamide,Total Body Irradiation (TBI)–MAC–MUD - Version 2                                                                              | Active   |
| Cyclophosphamide,Total Body Irradiation (TBI)–MAC–SIB - Version 2                                                                              | Active   |
| DA (50/100) (3+8) Course 2 Induction (AML-17) - Version 4                                                                                      | Active   |
| DA(60/100) 3+10: Course 1 Induction (AML-17) - Version 5                                                                                       | Active   |
| Dabrafenib Monotherapy - Version 3                                                                                                             | Active   |
| Dacarbazine (1.2g/m <sup>2</sup> ) -21 day - Version 2                                                                                         | Inactive |
| Dacomitinib Monotherapy - Version 1                                                                                                            | Active   |
| DACTINomycin - Version 2                                                                                                                       | Active   |
| Daratumumab (IV), Bortezomib and Dexamethasone Therapy - Version 1                                                                             | Inactive |
| Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy - Version 1                                                             | Active   |
| Daratumumab (SC 1800mg), Bortezomib and Dexamethasone - Version 1                                                                              | Active   |
| Daratumumab Monotherapy - Version 3                                                                                                            | Active   |
| Daratumumab SC Monotherapy - Version 2                                                                                                         | Active   |
| Decitabine Monotherapy - Version 1                                                                                                             | Inactive |
| Degarelix-28 day - Version 3                                                                                                                   | Active   |
| Dexamethasone, riTUXimab and Cyclophosphamide (DRC) - Version 1                                                                                | Inactive |
| DOCEtaxel /Cyclophosphamide (TC)-21 day - Version 5                                                                                            | Active   |
| DOCEtaxel 75mg/m <sup>2</sup> –Prednisolone Combination - Version 1                                                                            | Inactive |
| DOCEtaxel Monotherapy 100mg/m <sup>2</sup> - 21 day - Version 2                                                                                | Inactive |
| DOCEtaxel Monotherapy 50mg/m <sup>2</sup> – 14 day cycle - Version 4                                                                           | Inactive |
| DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle - Version 2                                                                           | Active   |
| DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days - Version 6                                                                             | Active   |
| DOCEtaxel, CIsplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy - Version 2                                                         | Inactive |
| DOCEtaxel,CISplatin, 5-Fluorouracil and Radiotherapy - Version 3                                                                               | Active   |
| Dose Adjusted R-EPOCH - Version 3                                                                                                              | Inactive |
| Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day (DD AC-T) - Version 7                          | Active   |
| Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) - Version 2 | Active   |
| Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day (DD AC-T) - Version 6                            | Active   |
| Dose Dense DOXOrubicin, Cyclophosphamide (AC60/600) 14 day followed by weekly PACLitaxel and Trastuzumab Therapy (DD AC-TH) - Version 3        | Active   |
| DOXOrubicin (25mg/m <sup>2</sup> /day) and CIsplatin (100mg/m <sup>2</sup> )-21 day cycle - Version 1                                          | Inactive |
| DOXOrubicin (60) and Ifosfamide - Version 1                                                                                                    | Inactive |
| DOXOrubicin (60mg/m <sup>2</sup> ) - Version 3                                                                                                 | Active   |
| DOXOrubicin (75) and Ifosfamide - Version 2                                                                                                    | Inactive |
| DOXOrubicin 50mg/m <sup>2</sup> /Docetaxel 75mg/m <sup>2</sup> (AT 50/75)-21 day cycle - Version 1                                             | Inactive |
| DOXOrubicin 75mg/m <sup>2</sup> Monotherapy - Version 2                                                                                        | Active   |
| DOXOrubicin, and Cyclophosphamide (AC 60/600) - 21 day - Version 2                                                                             | Active   |
| DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab (AC-TH) - Version 2                 | Active   |
| DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) - Version 3                                 | Active   |
| Durvalumab Monotherapy 10mg/Kg-14 Day - Version 2                                                                                              | Active   |
| Durvalumab Monotherapy 1500mg – 28 Day - Version 2                                                                                             | Active   |
| EMA/CO Therapy (Etoposide, Methotrexate, DACTINomycin, Cyclophosphamide, vinCRISTine) - Version 1                                              | Inactive |
| EMA/EP Therapy (Etoposide Methotrexate DACTINomycin/Etoposide CIsplatin) - Version 2                                                           | Inactive |

## Regimen list

| Regimen                                                                                                | Status   |
|--------------------------------------------------------------------------------------------------------|----------|
| Encorafenib and Binimetinib - Version 1                                                                | Inactive |
| Enzalutamide Monotherapy - Version 3                                                                   | Active   |
| EpiRUBicin 75 + Cyclophosphamide (EC75) -21 day - Version 2                                            | Active   |
| EpiRUBicin 90 + Cyclophosphamide (EC90)-21 day - Version 2                                             | Active   |
| EpiRUBicin, CISplatin and 5-Fluorouracil (ECF) - ADJ -21 day - Version 1                               | Active   |
| EpiRUBicin, CISplatin and 5-Fluorouracil (ECF) -21 day LA/M - Version 2                                | Active   |
| EpiRUBicin, Oxaliplatin and 5-Fluorouracil (EOF)- 21 day - Version 1                                   | Inactive |
| Epirubicin, Oxaliplatin and Capecitabine (EOX) -21 day - Version 2                                     | Inactive |
| EriBULin Monotherapy - Version 3                                                                       | Active   |
| Erlotinib Monotherapy - Version 3                                                                      | Active   |
| Escalated Dose BEACOPP 21 day - Version 2                                                              | Inactive |
| ESHAP - Version 3                                                                                      | Active   |
| Etoposide and CISplatin 20mg/m <sup>2</sup> (EP) 5 day - Version 3                                     | Inactive |
| Everolimus and Exemestane - Version 2                                                                  | Active   |
| Everolimus Monotherapy - Version 2                                                                     | Active   |
| Exemestane Monotherapy Adj - Version 2                                                                 | Active   |
| Exemestane Monotherapy Met - Version 2                                                                 | Active   |
| FLAG Therapy - Version 4                                                                               | Active   |
| FLAG: Ida 8mg/m <sup>2</sup> - Version 7                                                               | Active   |
| FLOT -14 day NAdj - Version 5                                                                          | Active   |
| FLOT-14 day Adj - Version 5                                                                            | Active   |
| FLOX - Version 1                                                                                       | Active   |
| Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL - Version 2  | Active   |
| Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL - Version 1       | Active   |
| Fludarabine, cyclophosphamide and ritUXimab (FC IV+R) - Version 3                                      | Active   |
| Fludarabine, cyclophosphamide and ritUXimab (FC Oral +R) - Version 1                                   | Active   |
| Fludarabine,Busulfan,ATG Grafalon® – RIC – MUD - Version 1                                             | Active   |
| Fludarabine,Busulfan,ATG Grafalon® – RIC –SIB - Version 2                                              | Active   |
| Fludarabine,Melphalan,Alemtuzumab-RIC-MUD - Version 1                                                  | Active   |
| Fludarabine,Melphalan,Alemtuzumab-RIC-SIB - Version 1                                                  | Active   |
| FOLFIRI 14 day - Version 5                                                                             | Active   |
| FOLFIRINOX - Version 4                                                                                 | Active   |
| FOLFOX-4 14 day Adj - Version 6                                                                        | Inactive |
| FOLFOX-4 14 day Met - Version 4                                                                        | Inactive |
| FOLFOXIRI - Version 4                                                                                  | Active   |
| Fulvestrant - Version 2                                                                                | Active   |
| Gefitinib Monotherapy - Version 1                                                                      | Active   |
| Gemcitabine (1000mg/m <sup>2</sup> ) and RT - Version 2                                                | Inactive |
| Gemcitabine (1000mg/m <sup>2</sup> ) and CARBOplatin (AUC 4) - 21 day - Version 5                      | Active   |
| Gemcitabine (1000mg/m <sup>2</sup> ) and CARBOplatin (AUC 5)- 21 day - Version 4                       | Active   |
| Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (25mg/m <sup>2</sup> ) - 21 day - Version 3         | Active   |
| Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (70mg/m <sup>2</sup> ) Therapy- 28 day - Version 2  | Active   |
| Gemcitabine (1000mg/m <sup>2</sup> ) Monotherapy - 28 day Adj - Version 3                              | Inactive |
| Gemcitabine (1000mg/m <sup>2</sup> ) Monotherapy - 28 day Met - Version 3                              | Inactive |
| Gemcitabine (1000mg/m <sup>2</sup> ) Monotherapy - 56 day - Version 2                                  | Inactive |
| Gemcitabine (1000mg/m <sup>2</sup> ), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg - 21 day - Version 3 | Inactive |
| Gemcitabine (1250mg/m <sup>2</sup> ) and CISplatin (75mg/m <sup>2</sup> )- 21 day - Version 3          | Active   |
| Gemcitabine (1250mg/m <sup>2</sup> ) and CISplatin (80mg/m <sup>2</sup> ) - 21 day - Version 1         | Inactive |
| Gemcitabine (1250mg/m <sup>2</sup> ) Monotherapy - 21 day - Version 2                                  | Active   |
| Gemcitabine (400mg/m <sup>2</sup> ) and RT - Version 2                                                 | Inactive |
| Gemcitabine (600mg/m <sup>2</sup> ) and RT-7 day - Version 3                                           | Active   |
| Gemcitabine and CARBOplatin (AUC2) - 21 days - Version 3                                               | Active   |
| Gemcitabine and DOCEtaxel - 21 day - Version 2                                                         | Active   |
| Goserelin 10.8mg-12 weeks - Version 3                                                                  | Active   |
| Goserelin 3.6mg-28 day - Version 2                                                                     | Active   |
| High Dose Cytarabine - Version 3                                                                       | Active   |
| High Dose Melphalan Conditioning for Autologous Stem Cell Transplant - Version 1                       | Active   |

## Regimen list

| Regimen                                                                                                            | Status   |
|--------------------------------------------------------------------------------------------------------------------|----------|
| Ibrutinib Therapy CLL / Waldenström's macroglobulinaemia - Version 2                                               | Active   |
| Ibrutinib Therapy Mantle Cell Lymphoma - Version 2                                                                 | Active   |
| ICE (Ifosfamide, CARBOplatin and Etoposide) - Version 3                                                            | Active   |
| Idelalisib Monotherapy - Version 1                                                                                 | Active   |
| Imatinib - GIST Adj - Version 2                                                                                    | Inactive |
| Imatinib - GIST Met - Version 2                                                                                    | Active   |
| Inotuzumab ozogamicin Monotherapy - Version 1                                                                      | Inactive |
| Intermediate Dose Cytarabine - Version 4                                                                           | Active   |
| Intrathecal Methotrexate for CNS prophylaxis in GTN - Version 1                                                    | Inactive |
| Intravenous Vinorelbine Monotherapy - 21 day - Version 3                                                           | Active   |
| Ipilimumab Monotherapy - Version 4                                                                                 | Active   |
| Irinotecan Monotherapy - 21 days - Version 2                                                                       | Inactive |
| Ixazomib, Lenalidomide and Dexamethasone- 28 day - Version 2                                                       | Active   |
| Lapatinib and Capecitabine - Version 1                                                                             | Active   |
| LEAM Autologous Transplant Conditioning Regimen - Version 3                                                        | Inactive |
| Lenalidomide 25mg and Dexamethasone- 28 day - Version 1                                                            | Active   |
| Lenvatinib -DTC Therapy - Version 3                                                                                | Active   |
| Letrozole Monotherapy Adj - Version 4                                                                              | Active   |
| Letrozole Monotherapy Met - Version 4                                                                              | Active   |
| Letrozole Monotherapy NAdj - Version 3                                                                             | Active   |
| Leuprorelin 11.25mg-12 weeks - Version 3                                                                           | Active   |
| Leuprorelin 22.5mg-12 weeks - Version 3                                                                            | Active   |
| Leuprorelin 3.75mg-28 days - Version 2                                                                             | Active   |
| Leuprorelin 30mg-24 weeks - Version 2                                                                              | Active   |
| Leuprorelin 45mg-24 week - Version 3                                                                               | Active   |
| Leuprorelin 7.5mg-28 day - Version 2                                                                               | Active   |
| Methotrexate 8 day Charing Cross Regimen - Version 2                                                               | Active   |
| Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -14 Days - Version 1                                       | Inactive |
| Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days Adj - Version 1                                   | Inactive |
| Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days Met - Version 1                                   | Inactive |
| Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days NAdj - Version 1                                  | Inactive |
| Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy - Version 1                                            | Inactive |
| Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy - Version 1                                     | Inactive |
| Midostaurin Maintenance - Version 1                                                                                | Inactive |
| Mifamurtide - Version 1                                                                                            | Inactive |
| Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone – Weekly Therapy - Version 3                        | Active   |
| Modified FOLFIRINOX - Version 2                                                                                    | Active   |
| Modified FOLFOX-6 14 day Adj - Version 9                                                                           | Active   |
| Modified FOLFOX-6 14 day Met - Version 8                                                                           | Active   |
| Modified FOLFOX-6 Chemoradiation-14 day - Version 3                                                                | Active   |
| Modified Roswell Park (Fluorouracil 500mg/m <sup>2</sup> and Folinic Acid 50mg weekly x 6) Regimen Adj - Version 3 | Active   |
| Modified Roswell Park (Fluorouracil 500mg/m <sup>2</sup> and Folinic Acid 50mg weekly x 6) Regimen Met - Version 3 | Active   |
| Nab-Paclitaxel (Abraxane) and Gemcitabine - 28 day - Version 2                                                     | Inactive |
| Nab-PACLitaxel (Abraxane®) Monotherapy– 21 day - Version 2                                                         | Active   |
| Neoadjuvant DOCETaxel, CISplatin,5-Fluorouracil and Chemoradiation and Surgery - Version 3                         | Inactive |
| Neratinib - Version 1                                                                                              | Inactive |
| Nivolumab 1mg/kg Ipilimumab 3mg/kg - Version 3                                                                     | Active   |
| Nivolumab 3mg/kg with Ipilimumab 1mg/kg - Version 2                                                                | Active   |
| Nivolumab Monotherapy 240mg - 14 days (6 cycles) - Version 4                                                       | Active   |
| Nivolumab Monotherapy 240mg - 14 days Adj (26 cycles) - Version 3                                                  | Active   |
| Nivolumab Monotherapy 480mg-28 days (3 cycles) - Version 3                                                         | Active   |
| Nivolumab Monotherapy 480mg-28 days Adj (13 cycles) - Version 3                                                    | Active   |
| Obinutuzumab and Bendamustine-28 day cycle - Version 1                                                             | Active   |
| Obinutuzumab and Chlorambucil - Version 2                                                                          | Active   |

## Regimen list

| Regimen                                                                                               | Status   |
|-------------------------------------------------------------------------------------------------------|----------|
| Obinutuzumab and CHOP-21 day - Version 2                                                              | Active   |
| Obinutuzumab Cyclophosphamide vinCRISTine and prednisoLONE (O-CVP)-21 days - Version 2                | Active   |
| Obinutuzumab Maintenance Therapy-56 day - Version 2                                                   | Active   |
| Olaparib (Capsule) Monotherapy - Version 1                                                            | Inactive |
| Oral Etoposide - Version 3                                                                            | Active   |
| Oral Vinorelbine Monotherapy-7 days - Version 4                                                       | Active   |
| Osimertinib Monotherapy - Version 1                                                                   | Active   |
| PACLiTaxel (80) and Trastuzumab-7 day (12 weeks) - Version 3                                          | Active   |
| PACLiTaxel 80mg/m <sup>2</sup> Day 1, 8 and 15 Monotherapy-28 Day - Version 2                         | Active   |
| PACLiTaxel Monotherapy 80mg/m <sup>2</sup> Day 1, 8, 15 and 22 – 28 Day - Version 8                   | Active   |
| PACLiTaxel/CISPlatin alternating with PACLiTaxel/Etoposide (TP/TE) - Version 1                        | Inactive |
| Palbociclib-28 day - Version 3                                                                        | Active   |
| Panitumumab 6mg/kg - Version 4                                                                        | Active   |
| Panitumumab 6mg/kg and FOLFIRI -14 day - Version 4                                                    | Active   |
| Panitumumab 6mg/kg and Modified FOLFOX-6 – 14 day - Version 5                                         | Active   |
| PAZOPanib - Version 1                                                                                 | Active   |
| Pegylated Liposomal DOXOrubicin 20 mg/m <sup>2</sup> (CAELYX)® 21 days - Version 2                    | Active   |
| Pegylated Liposomal DOXOrubicin 50mg/m <sup>2</sup> (CAELYX) 28 days - Version 4                      | Active   |
| Pembrolizumab 200mg Monotherapy (4 cycles) - Version 7                                                | Active   |
| Pembrolizumab 200mg Monotherapy Adj (18 cycles) - Version 5                                           | Active   |
| Pembrolizumab 400mg Monotherapy (2 cycles) - Version 7                                                | Active   |
| Pembrolizumab 400mg Monotherapy Adj (9 cycles) - Version 5                                            | Active   |
| Pembrolizumab, CARBOPlatin (AUC 5) and 5-Fluorouracil Therapy - Version 1                             | Active   |
| Pembrolizumab, CISPlatin and 5-Fluorouracil Therapy - Version 1                                       | Active   |
| Pembrolizumab, PACLiTaxel and CARBOPlatin (AUC 6) - Version 3                                         | Active   |
| Pembrolizumab, PEMEtrexed and CARBOPlatin (AUC 5) - Version 2                                         | Active   |
| PEMEtrexed and CARBOPlatin - Version 5                                                                | Active   |
| PEMEtrexed and CISPlatin - Version 3                                                                  | Active   |
| PEMEtrexed Monotherapy - Version 2                                                                    | Active   |
| Pertuzumab and Trastuzumab and Chemotherapy - 21 day cycle Adj - Version 3                            | Active   |
| Pertuzumab and Trastuzumab and Chemotherapy - 21 day cycle NAdj - Version 3                           | Active   |
| Pertuzumab and Trastuzumab and DOCEtaxel Therapy - 21 day - Version 4                                 | Active   |
| Pertuzumab Trastuzumab and Vinorelbine - Version 3                                                    | Active   |
| Pertuzumab Trastuzumab and Weekly PACLiTaxel - 21 day cycle - Version 4                               | Active   |
| Pixantrone Therapy - Version 1                                                                        | Inactive |
| Pomalidomide and Dexamethasone - Version 3                                                            | Active   |
| Procarbazine Lomustine and VinCRISTine (PCV) - Version 3                                              | Active   |
| QUASAR (Modified) Fluorouracil (370mg/m <sup>2</sup> ) and Folinic Acid (50mg) Weekly Adj - Version 5 | Active   |
| QUASAR (Modified) Fluorouracil (370mg/m <sup>2</sup> ) and Folinic Acid (50mg) Weekly Met - Version 4 | Active   |
| R- miniCHOP - 21 days - Version 2                                                                     | Inactive |
| R-CEOP – 21 days - Version 1                                                                          | Inactive |
| R-CHOP - 21 days - Version 6                                                                          | Active   |
| R-CHOP-14 days - Version 7                                                                            | Active   |
| R-CODOX-M (Patients >65 years) - Version 1                                                            | Inactive |
| R-CODOX-M (Patients ≤65yrs) - Version 1                                                               | Inactive |
| R-CVP – 21 days RiTUXimab, Cyclophosphamide vinCRISTine and Prednisolone - Version 2                  | Active   |
| R-DHAP - Version 1                                                                                    | Active   |
| Regorafenib Monotherapy - Version 3                                                                   | Active   |
| R-ESHAP - Version 5                                                                                   | Active   |
| R-Gemcitabine (1000mg/m2) Oxaliplatin - 14 day - Version 1                                            | Inactive |
| Ribociclib-28 day - Version 1                                                                         | Active   |
| R-ICE (RiTUXimab), Ifosfamide, CARBOPlatin and Etoposide) - Version 4                                 | Active   |
| RiTUXimab (S/C 1400mg) Maintenance - 56 day - Version 2                                               | Active   |

## Regimen list

| Regimen                                                                                               | Status   |
|-------------------------------------------------------------------------------------------------------|----------|
| RiTUXimab (S/C 1400mg) Maintenance - 84 day - Version 2                                               | Active   |
| RiTUXimab 375 mg/m <sup>2</sup> - 7 day - Version 2                                                   | Active   |
| riTUXimab 375 mg/m <sup>2</sup> Combination Therapy-21 day - Version 2                                | Active   |
| RiTUXimab 375 mg/m <sup>2</sup> Maintenance Therapy- 56 day - Version 3                               | Active   |
| RiTUXimab 375mg/m <sup>2</sup> - Follicular Lymphoma (every 2 months) - Version 2                     | Inactive |
| RiTUXimab 375mg/m <sup>2</sup> - Follicular Lymphoma (every 3 months) - Version 2                     | Inactive |
| RiTUXimab 375mg/m <sup>2</sup> - Follicular Lymphoma (once weekly for four weeks) - Version 2         | Inactive |
| RiTUXimab 375mg/m <sup>2</sup> Maintenance-84 day - Version 2                                         | Active   |
| RiTUXimab and Bendamustine - Version 3                                                                | Active   |
| riTUXimab S/C, (R-CHOP) Therapy– 21 Days - Version 1                                                  | Active   |
| riTUXimab** Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP) - Version 1                          | Inactive |
| Ruxolitinib Monotherapy - Version 1                                                                   | Inactive |
| SORafenib - Version 2                                                                                 | Active   |
| SUNitinib 37.5mg - Version 1                                                                          | Active   |
| SUNitinib 50mg - Version 1                                                                            | Active   |
| Tamoxifen Monotherapy Adj - Version 2                                                                 | Active   |
| Tamoxifen Monotherapy Met - Version 2                                                                 | Active   |
| Temozolomide Recurrent Therapy - Version 2                                                            | Active   |
| Temozolomide with Radiotherapy (RT) and Adjuvant Therapy - Version 2                                  | Active   |
| Temozolomide with Radiotherapy (RT) and Adjuvant Therapy - Patients greater than 65 years - Version 2 | Active   |
| Temsirolimus Monotherapy - Version 3                                                                  | Active   |
| Topotecan Monotherapy – 5 day - Version 3                                                             | Inactive |
| Topotecan Monotherapy – Weekly - Version 3                                                            | Active   |
| Topotecan Oral Monotherapy - Version 1                                                                | Inactive |
| Trabectedin and Pegylated Liposomal DOXOrubicin (PLD) - Version 2                                     | Inactive |
| Trabectedin Monotherapy - Version 1                                                                   | Inactive |
| Trametinib and Dabrafenib Adj - Version 1                                                             | Active   |
| Trametinib and Dabrafenib Met - Version 2                                                             | Active   |
| Transcription only. See original prescription. - Version 1                                            | Active   |
| Trastuzumab (IV) Monotherapy - 21 days Adj - Version 4                                                | Active   |
| Trastuzumab (IV) Monotherapy - 7 days - Version 3                                                     | Active   |
| Trastuzumab (IV) Monotherapy- 21 days Met - Version 4                                                 | Active   |
| Trastuzumab 5-Fluorouracil and CISplatin - 21 days - Version 4                                        | Active   |
| Trastuzumab Emtansine (Kadcyla®) - 21 days - Version 3                                                | Active   |
| Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer - Version 5                               | Active   |
| Trastuzumab Subcutaneous 21 days - Early Breast Cancer - Version 5                                    | Active   |
| Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation - Version 1                                | Inactive |
| Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction - Version 1                                    | Inactive |
| Triptorelin 11.25mg-12 weeks - Version 2                                                              | Active   |
| Triptorelin 22.5mg-24 weeks - Version 2                                                               | Active   |
| Triptorelin 3mg-28 day - Version 1                                                                    | Active   |
| Two Day Etoposide CISplatin (EP) - Version 1                                                          | Inactive |
| Vandetanib Therapy - Version 2                                                                        | Active   |
| Vemurafenib Monotherapy - Version 3                                                                   | Active   |
| Venetoclax Monotherapy - Version 2                                                                    | Active   |
| VinBLASTine and Methotrexate - Version 1                                                              | Inactive |
| Vinorelbine 30 (Day 1,8,15) and CISplatin 80 (Day1) Therapy- 21 day - Version 1                       | Inactive |
| Vinorelbine and CISplatin Therapy - 28 day - Version 1                                                | Inactive |
| Vismodegib Monotherapy - Version 3                                                                    | Active   |
| Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m <sup>2</sup> with Radiotherapy - Version 7                | Active   |
| Zoledronic Acid Monotherapy - Version 2                                                               | Active   |